DDAVP in the Reduction of Post-operative Ecchymosis in Rhinoplasty
- Registration Number
- NCT01982760
- Lead Sponsor
- University Hospitals Cleveland Medical Center
- Brief Summary
This is study looking at the use of a medication, Desmopressin acetate (DDAVP), to reduce bleeding, swelling, and bruising in patients undergoing cosmetic nose surgery. DDAVP is a drug used in patients with bleeding disorders. It works by activating molecules in the blood stream called platelets that promote clotting. In the study, participants who are have cosmetic nose surgery (rhinoplasty) will be randomly assigned to receive or not receive medication. Photographs taken before and shortly after surgery will be evaluated for the amount of bruising and swelling. Patients with heart, lung, kidney, or liver problems are not eligible to participate.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 14
- Undergoing Rhinoplasty where nasal bone osteotomy is necessary
- Heart Disease
- Renal Disease with decreased GFR
- Liver Disease
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description DDAVP DDAVP Arm receiving DDAVP prior to the operation. Drug is administered intravenously at .3mcg per kg, over 30 minutes prior to the operation.
- Primary Outcome Measures
Name Time Method Reduction in Ecchymosis and Swelling surgery to 8 days post-operatively Photographs taken preoperatively at 1 day and 8 days post-operatively will be analyzed for bruising
- Secondary Outcome Measures
Name Time Method Patient Behavior Factors Surgery to 3 weeks post-operatively Looking at the time it takes for patients to feel comfortable wearing makeup, going out in public, and returning to work
Trial Locations
- Locations (1)
Lyndhurst Surgery Center
🇺🇸Lyndhurst, Ohio, United States